Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1963 1
1967 1
1968 2
1969 4
1971 6
1972 8
1973 5
1974 7
1975 10
1976 7
1977 13
1978 12
1979 9
1980 8
1981 12
1982 12
1983 11
1984 8
1985 10
1986 25
1987 15
1988 17
1989 12
1990 12
1991 13
1992 19
1993 10
1994 15
1995 9
1996 10
1997 8
1998 7
1999 5
2000 6
2001 15
2002 6
2003 9
2004 12
2005 11
2006 11
2007 6
2008 5
2009 5
2010 5
2011 7
2012 5
2013 2
2014 1
2015 1
2016 2
2017 4
2018 2
2019 4
2020 2
2021 3
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Results by year

Filters applied: . Clear all
Page 1
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. Among authors: brenner bm. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2021 Sep 18;398(10305):1053-1064. doi: 10.1016/S0140-6736(21)01921-8. Epub 2021 Aug 27. Lancet. 2021. PMID: 34461040 Free PMC article.
Need kidneys fail?
Brenner BM. Brenner BM. West J Med. 1986 Oct;145(4):512-3. West J Med. 1986. PMID: 3788143 Free PMC article. No abstract available.
Biologically active atrial peptides.
Ballerman BJ, Brenner BM. Ballerman BJ, et al. Among authors: brenner bm. J Clin Invest. 1985 Dec;76(6):2041-8. doi: 10.1172/JCI112206. J Clin Invest. 1985. PMID: 3001138 Free PMC article. Review. No abstract available.
Defining renal risk.
Taal MW, Brenner BM. Taal MW, et al. Among authors: brenner bm. Curr Opin Nephrol Hypertens. 2007 Nov;16(6):554-6. doi: 10.1097/MNH.0b013e3282f09f26. Curr Opin Nephrol Hypertens. 2007. PMID: 18089970 Review. No abstract available.
Glomerular actions of angiotensin II.
Ichikawa I, Brenner BM. Ichikawa I, et al. Among authors: brenner bm. Am J Med. 1984 May 31;76(5B):43-9. doi: 10.1016/0002-9343(84)90882-9. Am J Med. 1984. PMID: 6203406 Review.
The clinical importance of nephron mass.
Luyckx VA, Brenner BM. Luyckx VA, et al. Among authors: brenner bm. J Am Soc Nephrol. 2010 Jun;21(6):898-910. doi: 10.1681/ASN.2009121248. Epub 2010 Feb 11. J Am Soc Nephrol. 2010. PMID: 20150537 Review.
Glomerular response to renal injury.
Brenner BM, Goldszer RC, Hostetter TH. Brenner BM, et al. Contrib Nephrol. 1982;33:48-66. doi: 10.1159/000407066. Contrib Nephrol. 1982. PMID: 6749423 Review. No abstract available.
444 results